Recent studies demonstrated aberrant IL6 production and secretion in a large variety of malignant tumours, including breast cancer [7], ovarian cancer [8], lung cancer [9] and GBM [10–15], revealing the oncogenic effects of IL6 signalling. This evidence concerns the gene IL6 and breast cancer.